Literature DB >> 363104

Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).

P S Papavasiliou, G C Cotzias, V L Rosal, S T Miller.   

Abstract

The effects of the concomitant administration of N-n-propyl norapomorphine (NPA) and levodopa, with and without carbidopa, were studied in 12 patients with unsatisfactory symptom control. Double-blind evaluation of the effects of NPA with suboptimal doses of levodopa or levodopa plus carbidopa (Sinemet) showed a mean overall improvement of 44% (20% to 74%) in nine patients and improvement of the "on-off" effect in five. Dyskinesia diminished in some patients after diminution of basal medication. In three patients, plasma dopa and growth hormone patterns did not differ substantially with and without NPA. The magnitude and timing of the therapeutic and side effects did not correlate with the pattern of growth hormone secretion, which suggests that this hormone might not be instrumental in the induction of these effects. N-n-propyl norapomorphine is a useful adjunct in the long-term management of patients with unsatisfactory response to levodopa.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 363104     DOI: 10.1001/archneur.1978.00500360011002

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  3 in total

Review 1.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait.

Authors:  Catherine Cho; Mikhail Kunin; Koji Kudo; Yasuhiro Osaki; C Warren Olanow; Bernard Cohen; Theodore Raphan
Journal:  J Neurophysiol       Date:  2009-12-30       Impact factor: 2.714

Review 3.  Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease and Dopa-Responsive Dystonia.

Authors:  Ichiro Kawahata; Kohji Fukunaga
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.